Our Approach

Our Discovery Engine

A proprietary in-house discovery platform enables us to see the real-world interaction between drug and target in rapid, sequential, structural SNÅPshots. With each SNÅP, we bring speed, clarity, and focus to structure-based drug design.

Explore the engine
SNÅPDISCOVERY ENGINE

Precision by Design

Driven by clear patient needs

Using our SNÅP Discovery Engine, we drive towards innovative molecular structures that are designed to specifically address key drivers of a patient’s disease. Our next-generation candidates are designed to provide deeper responses, and in cancer, to overcome mechanisms of resistance to currently available treatments.

01

Target is inhibited by first-generation drug

02

Resistance mutation emerges blocking binding of the drug

03

Tyra drug designed to accommodate new active site architecture

04

Wild type and mutated form of target is inhibited by Tyra drug

FGFR Biology

Targeting FGFR with selectivity

Fibroblast Growth Factor Receptor (FGFR) signaling drives growth in a range of cancers. Our candidates are designed for FGFR-selectivity — interrupting the signal while sparing off-target receptors.

EXTRACELLULARINTRACELLULARFGFFGFR kinaseProliferation & survivalFGFR3-selectiveinhibition

FGFR alterations occur in roughly 7% of cancers. FGFR3-selectivity is designed to interrupt this signaling while avoiding the off-target toxicity of pan-FGFR inhibitors.

Speed with Clarity

Quick and routine data generation

Full structural SNÅPshots for our discovery compounds are obtained in as little as 7 days, rather than weeks to months. This enables us to rapidly iterate on designs week after week with a clear line of sight into how each modification moves us closer to our goal.

7DAYS

full structural SNÅPshots in as little as 7 days

The 7-Day Loop

One iterative loop, in as little as 7 days

Each SNÅP resolves a structural snapshot into focus — design, co-crystallize, capture, refine — then begins again. Scroll to follow the loop.

DAY 1

  1. Day 1

    Design

    We design a discovery compound targeting the real-world interaction between drug and target.

  2. Days 2–4

    Co-crystallize

    Advancements in protein crystallography let us grow and immortalize crystals in days, not weeks.

  3. Days 5–6

    Capture the SNÅPshot

    We capture a full structural SNÅPshot — an empirical, real-world picture of the compound bound to its target.

  4. Day 7

    Refine

    The structure reveals opportunities to refine the design, down to a tenth of an angstrom — and the loop begins again.

Empirical, Real-World Data

Focused generation of empirical (real-world) data

Our engine prioritizes a select number of critical assays, with an emphasis on datasets that can drive precise design refinements. Together, these data form a full picture or structural “SNÅPshot” for each discovery compound that reveals clear opportunities to refine its molecular design, down to a tenth of an angstrom (Å).

SNÅPshotChemistrySNÅP designCrystallographystructureAssayspotencyIn vivomodels

Refined down to

2.6 Å

Experience into Innovation

Experience translated into innovation

We have distilled decades of experience into process optimizations and innovations. Our advancements to the art of protein crystallography are key to reducing the time-to-structure from multiple weeks to days:

CRYSTALCYCLE1234

  1. Multi-species crystal seed stocks rapidly induce crystallization

  2. Proprietary additives in sparse matrix chemical screens enhance crystal packing and growth

  3. Crystals are immortalized via chemical stabilization. Banked crystals are ready for compound addition.

  4. Immortalized crystals are fed back into multi-species crystal seed stocks

Purpose-Built Pipeline

Leveraging insights from rapid, sequential SNÅPshots, we move with angstrom-level precision towards developing selective inhibitors designed to deliver deeper, more durable responses for people.

LEARN ABOUT OUR TARGETS